New Indications for TIPSs: What Do We Know So Far?

J Clin Exp Hepatol. 2023 Sep-Oct;13(5):794-803. doi: 10.1016/j.jceh.2023.01.017. Epub 2023 Feb 10.

Abstract

Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent results have been achieved with this therapeutic strategy. The historical indications for TIPS placement, in the context of liver cirrhosis, such as refractory ascites and variceal bleeding are now well established and known. However, in recent years, new indications are emerging. These have been investigated and approved in some studies but are not yet included in guidelines and clinical practice. This review aims to highlight what is new for the role of TIPS in portal vein thrombosis (especially in patients awaiting liver transplantation), in recurrent ascites and not only refractory ascites, as a neoadjuvant therapy before abdominal surgery and, finally, in the setting of noncirrhotic portal hypertension. All these new aspects are addressed in this review with a critical approach based on the literature revision and clinical practice. Future research is needed to explore and validate the new role of TIPS in these scenarios.

Keywords: Budd-Chiari syndrome; portal hypertension; portal vein thrombosis; surgery; transjugular intrahepatic portosystemic shunt.

Publication types

  • Review